Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus

What Was Tested

Researchers studied Insulin Lispro in this randomized controlled trial publication.

Insulin lispro Mix75/25 (Mix75/25) is the first available insulin formulation in which both the rapid-acting and basal components are insulin analogues.

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

This randomized, multicenter, double-blind, crossover study monitored patients' postprandial glucodynamic response to Mix75/25 and human insulin 70/30 (70/30) after a standard test meal.

Eighty-four patients with type 2 diabetes participated in this study and were randomly assigned to 1 of 2 treatment sequence groups.

How the Study Was Run

The design is described as randomized, double-blind, crossover and multicenter.

The participants were allocated by chance, so the Insulin Lispro group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Insulin Lispro.

In the crossover set-up each of the participants took both Insulin Lispro and the comparison in turn, acting as their own control.

More than one site took part, so the participants came from several places.

Patients received an identical test meal on 4 occasions, completing 2 test meals for each treatment.

From these plasma glucose measurements, fasting plasma glucose, 2-hour postprandial glucose (2pp), 2-hour postprandial glucose excursion (2pp(ex)), maximum glucose excursion (Gex(max)), the area under the glucose concentration versus time curve from 0 to 4 hours (AUC4), and the area under the glucose excursion versus time curve from 0 to 4 hours (AUCex4) were calculated.

What Was Measured

The subject headings attached to it are Area Under Curve, Blood Glucose, Cross-Sectional Studies, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Insulin and Insulin Lispro.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin Lispro.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2000 (Clinical therapeutics), a journal based in United States.

More context: the Insulin Lispro compound page, all human trials.